pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,300 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT967Endpoints742BioPharma Dive283BioSpace181Fierce Biotech172onclive165globenewswire health73raps
therapy area
allOncology5602Rare Disease1251Cardiology1051Hematology936Immunology926Vaccines813Pulmonology
  • Iowa audit finds PBM kept over $100 million by inflating Medicaid drug costs
    A recent audit of Iowa's Medicaid program uncovered that a major pharmacy benefit manager used complex claim handling methods that led to higher costs for the state. The review of records from 201…
    STAT · 26d agoRegulatoryNegative↗ source
  • Kyverna Therapeutics aims to file first CAR-T cell therapy for autoimmune disease
    Kyverna Therapeutics is preparing what could become the first regulatory filing for a CAR-T cell therapy targeting an autoimmune condition. The company has been developing its miv-cel construct in…
    BioSpace · 26d agoRegulatoryPositive↗ source
← prev
page 35 of 92
next →
65
fda recalls41
fda medwatch32
fda press25
776
Psychiatry & CNS690
Ophthalmology343
Pain341
Endocrinology & Metabolism340
Infectious Disease328
  • UnitedHealth outlines AI rollout as quarterly results beat expectations
    UnitedHealth Group, a major health insurer, announced a substantial investment in artificial intelligence earlier this year. The company recently detailed how the technology is being integrated in…
    Endpoints · 26d agoPositive↗ source
  • House lawmakers support US trade panel's probe into China's biotech sector and pricing practices
    At least ten members of the U.S. House of Representatives have voiced support for a trade investigation targeting China’s biotechnology industry. The investigation, led by a U.S. trade panel, will…
    Endpoints · 26d agoRegulatoryNeutral↗ source
  • J&J and AbbVie also considered AtaiBeckley before Lilly’s $2.8 B acquisition
    Johnson & Johnson and AbbVie were reported to have evaluated AtaiBeckley as a potential target in the psychedelic market. The companies did not submit an offer before Eli Lilly closed its $2.8 bil…
    Endpoints · 26d agoDealNeutral↗ source
  • Kolon’s cell-based gene therapy misses key endpoints in phase 3 osteoarthritis trial
    Kolon TissueGene reported that its phase 3 study of TG‑C, a cell‑based gene therapy for knee osteoarthritis, failed to meet its co‑primary endpoints. Patients receiving the therapy showed no statis…
    Fierce Biotech · 26d agoNegative readoutNegative↗ source
  • Scribe targets $96 million from Nasdaq IPO as Scholar Rock awaits site classification for apitegromab
    Scribe, a gene-editing biotech, announced plans for a Nasdaq initial public offering that could raise roughly $96 million. The company said it would price the shares at $14 each, which is the midp…
    Endpoints · 26d agoDealNeutral↗ source
  • HHS vaccine committee receives new charter amid broader health policy updates
    The U.S. Health and Human Services vaccine advisory panel has been granted a new charter, a change that was noted quietly in a recent health newsletter. The same briefing highlighted other policy…
    STAT · 26d agoRegulatoryNeutral↗ source
  • Pandemics Should Be Treated as National Security Threats, Experts Argue
    In an opinion piece, David Blumenthal and James A. Morone argue that pandemics should be classified and addressed as national security threats rather than solely health-care challenges. They note…
    STAT · 26d agoPositive↗ source
  • FDA maintains focus on Taylor Farms lettuce as source of cyclospora outbreak despite false‑positive test
    Federal health officials said on Monday that the FDA continues to target shredded lettuce from Taylor Farms as the likely source of a multistate cyclospora outbreak, even after a laboratory result…
    STAT · 25d agoRegulatoryNeutral↗ source
  • Physician blames U.S. health insurance failures after husband's suicide
    Joy Evers, an emergency physician, recounts the death of her husband Randy by suicide, describing how she expected her family’s high-quality commercial health insurance to ensure he received timely…
    STAT · 26d agoNegative↗ source
  • Fugitive ex-doctor arrested after two decades posing as biotech executive
    Federal and Rhode Island authorities arrested Ronald Fischer, 70, after tracking a 56-foot sailboat off New Jersey. He had been on the run for about 20 years. Fischer, a former anesthesiologist, v…
    STAT · 26d agoRegulatoryNegative↗ source
  • Latigo Biotherapeutics plans IPO to fund phase 3 trials of non-opioid pain drug LTG-001
    Latigo Biotherapeutics announced it is preparing an initial public offering to raise capital for its clinical-stage, non-opioid pain management pipeline. The company highlighted its oral Nav1.8 in…
    Fierce Biotech · 27d agoDealNeutral↗ source
  • Geopolitical uncertainty dampens UK biotech IPO outlook despite record Q2 venture funding
    Geopolitical uncertainty continues to weigh on the sentiment around initial public offerings for British biotech companies, according to an industry leader speaking to Fierce. At the same time, th…
    Fierce Biotech · 27d agoNeutral↗ source
  • Abbott reports cyberattack on cancer diagnostics and LabCentral portal, says operations unaffected
    Abbott announced that a cyber incident on July 16 accessed a limited number of internal systems in its cancer diagnostics unit. The company said the breach does not affect product availability, ma…
    Fierce Biotech · 27d agoNegative↗ source
  • Eli Lilly’s $2.8 bn purchase of AtaiBeckley adds psychedelic candidate BPL‑003, sparking optimism for broader mental‑health drug pipeline
    Eli Lilly announced it has acquired AtaiBeckley for $2.8 billion, bringing the privately held biotech’s lead psychedelic program into its portfolio. The deal gives Lilly access to BPL‑003, an intr…
    Fierce Biotech · 28d agoDealPositive↗ source
  • U.S. Military's New Testosterone Screening Raises Health Concerns
    The Department of Defense announced a mandatory testosterone screening program for all service members, prompting discussion among medical experts. A urologist who studies men’s health cautions th…
    STAT · 27d agoNegative↗ source
  • STAT invites reader letters on primary care value, obesity as disease and broader health-care debates
    STAT’s First Opinion platform encourages readers to submit letters responding to its essays, fostering open, good‑faith discussion about health‑care topics. Recent letters, echoing comments from t…
    STAT · 28d agoNeutral↗ source
  • Biogen reports mixed Alzheimer’s trial results as industry sees new startup launches
    Biogen released data from its Alzheimer’s program that showed mixed outcomes, indicating some signals but also setbacks. The weekly newsletter also highlighted the launch of two new biotech startu…
    Endpoints · 28d agoNeutral↗ source
  • Abbott Beats Q2 Expectations with Strong Device and Diagnostic Sales, Raises Profit Forecast
    Abbott reported second‑quarter results that exceeded analysts' forecasts, easing concerns about potential impact of ACA subsidy cuts on medtech firms. Diagnostics revenue jumped 42% year‑over‑year…
    Fierce Biotech · 29d agoEarningsPositive↗ source
  • BlossomHill and Latigo lead a surge of biotech IPOs after summer dry spell
    After a seven‑month lull that left no biotech companies on the public markets last summer, the sector is seeing renewed activity. BlossomHill Therapeutics and Latigo have filed to list on Nasdaq,…
    Endpoints · 29d agoDealPositive↗ source
  • Sonothera reports ultrasound method delivers high levels of dystrophin in monkeys, a potential new route for Duchenne therapy
    A California startup, Sonothera, is proposing an ultrasound‑based approach to deliver genes for Duchenne muscular dystrophy treatment. The company says its technology can introduce full-size dystr…
    STAT · 29d agoPositive readoutNeutral↗ source
  • Dimerix acquires Mission's phase-2 ready AKI drug in $292 million deal
    Dimerix announced it has acquired the acute kidney injury candidate MTX652 from Mission Therapeutics in a deal valued at up to $292 million, including a $5 million upfront payment. Mission had com…
    Fierce Biotech · 29d agoDealPositive↗ source
  • Mid-size biotech firms urge White House to scrap CMS GLOBE and GUARD pricing proposals
    A group of midsized biotechnology companies met with officials from the White House and the Department of Health and Human Services this week. The companies presented a coordinated case to senior p…
    Endpoints · 28d agoRegulatoryNegative↗ source
  • Celcuity's Revtorpyk receives FDA approval, but launch delay pushes stock lower
    The FDA announced approval of Celcuity’s oncology candidate Revtorpyk on Tuesday, marking the company’s first cancer drug clearance. Analysts had broadly expected the approval and had priced the s…
    Endpoints · 29d agoApprovalNeutral↗ source